Form 4: X4 Pharmaceuticals COO Sells Shares to Cover Tax Obligations

Mary DiBiase, COO of X4 Pharmaceuticals, sold 15,409 shares of common stock on March 11, 2024, to cover personal income tax obligations related to the settlement of a restricted stock unit award.

Summary

• On March 11, 2024, Mary DiBiase, the Chief Operating Officer of X4 Pharmaceuticals, sold 15,409 shares of the company's common stock.
• The sale was executed at a weighted average price of $0.882 per share, with individual transactions ranging from $0.863 to $0.91.
• Following the transaction, DiBiase directly owns 291,752 shares of X4 Pharmaceuticals.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 2, 2023.
• The purpose of the sale was to cover personal income tax obligations arising from the settlement of a restricted stock unit award.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine transaction related to tax obligations and doesn't necessarily reflect a change in the executive's confidence in the company.

Industry Context

This is a routine Form 4 filing, indicating an insider transaction. It's common for executives to sell shares to cover tax obligations, especially after vesting of stock awards. The existence of a 10b5-1 plan suggests the sale was pre-planned and not based on current market information.

Stakeholder Impact

• The sale of shares by an executive could create short-term selling pressure on the stock, but the impact is likely to be minimal given the relatively small number of shares involved and the pre-planned nature of the transaction.

Key Dates